U.S. Food & Drug Administration (FDA) Clinical Pharmacology Corner Update: FDA Approves PORTRAZZA (necitumumab)

U.S. Food & Drug Administration (FDA) Clinical Pharmacology Corner Update: FDA Approves PORTRAZZA (necitumumab) Clinical Pharmacology Corner Banner *FDA Approves PORTRAZZA (necitumumab) in Combination with Gemcitabine and Cisplatin, for First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer* On November 24, 2015, the United States Food and Drug Administration (FDA) approved PORTRAZZA (necitumumab)Continue reading “U.S. Food & Drug Administration (FDA) Clinical Pharmacology Corner Update: FDA Approves PORTRAZZA (necitumumab)”

U.S. Food & Drug Administration (FDA) Clinical Pharmacology Corner Update: FDA Approves YONDELIS (trabectedin)

U.S. Food & Drug Administration (FDA) Clinical Pharmacology Corner Update: FDA Approves YONDELIS (trabectedin) Clinical Pharmacology Corner Banner *FDA Approves YONDELIS^® (trabectedin) for Advanced Soft Tissue Sarcoma Subtypes, Liposarcoma, and Leiomyosarcoma, With Prior Chemotherapy* On October 23, 2015, the United States Food and Drug Administration (FDA) approved YONDELIS (trabectedin) for the treatment of patients withContinue reading “U.S. Food & Drug Administration (FDA) Clinical Pharmacology Corner Update: FDA Approves YONDELIS (trabectedin)”

Clinical Pharmacology Corner Update: FDA Approves REXULTI (Brexpiprazole)

FDA Approves REXULTI® (Brexpiprazole) for the Treatment of Schizophrenia and Adjunctive Treatment of Major Depressive Disorder   On July 10, 2015, the FDA approved REXULTI (brexpiprazole) immediate-release tablets for the treatment of schizophrenia and the adjunctive treatment of major depressive disorder (MDD). Dosage and Administration Treatment of Schizophrenia: The recommended starting dose for REXULTI in theContinue reading “Clinical Pharmacology Corner Update: FDA Approves REXULTI (Brexpiprazole)”